c-erbB-4/HER4: Friend or foe?

Journal of Pathology

Volumn 200, Issue 3, 2003, Pages 279-281

  Gullick, William J ^a  

^a UNIVERSITY OF KENT   (United Kingdom)

Author keywords

Breast cancer; Growth factor; Growth factor receptor; Signal transduction; Tyrosine kinase inhibition

Indexed keywords

CANERTINIB; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; GAMMA UROGASTRONE; ISOENZYME; LIGAND; ONCOPROTEIN; PROTEIN TYROSINE KINASE; RECEPTOR PROTEIN; RIBOZYME;

ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL DIVISION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE MUTATION; GROWTH STIMULATION; HUMAN; ONCOGENE C ERB; PRIORITY JOURNAL; PROGNOSIS;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROGNOSIS; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 0038349045     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1335     Document Type: Article

References (26)

1. Witton CJ, Reeves JR, Going JJ, et al. Expression of the HER 1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003; 200: 290-297.
2. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Bio 2001; 2: 127-137.
3. Gullick WJ. The Type 1 growth factor receptors and their ligands considered as a complex system. Endocr-Relat Cancer 2001; 8: 75-82.
4. Junttila TT, Sundvall M, Maatta JA, et al. ErbB4 and its isoforms: selective regulation of growth factor responses by naturally occurring receptor variants. Trends Cardiovasc Med 2000; 10: 304-310.
5. Srinivasan R, Poulsom R, Hurst HC, et al. Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types. J Pathol 1998; 185: 236-245.
6. Zhou W, Carpenter G. ErbB-4: a receptor tyrosine kinase. Inflamm Res 2002; 51: 91-101.
7. Jones FE, Welte T, Fu XY, et al. ErbB4 signaling in the mammary gland is required for lobuloalveolar development and Stat5 activation during lactation. J Cell Biol 1999; 147: 77-87.
8. Wang LM, Kuo A, Alimandi M, et al. ErbB2 expression increases the spectrum and potency of ligand-mediated signal transduction through ErbB4. Proc Natl Acad Sci USA 1998; 95: 6809-6814.
9. Kainulainen V, Sundvall M, Maatta JA, et al. A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis. J Biol Chem 2000; 275: 8641-8649.
10. Tang CK, Goldstein DJ, Payne J, et al. ErbB-4 ribozymes abolish neuregulin-induced mitogenesis. Cancer Res 1998; 58: 3415-3422.
11. Tang CK, Concepcion XZW, Milan M, et al. Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo. Cancer Res 1999; 59: 5315-5322.
12. Sartor CI, Zhou H, Kozlowska E, et al. HER4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. Mol Cell Biol 2001; 21: 4265-4275.
13. Erlich S, Goldshmit Y, Lupowitz Z, et al. ErbB-4 activation inhibits apoptosis in PC12 cells. Neuroscience 2001; 107: 353-362.
14. Penington DJ, Bryant I, Riese DJ. Constitutively active ErbB4 and ErbB2 mutants exhibit distinct biological activities. Cell Growth Differ 2002; 13: 247-256.
15. Barker AJ, Gibson KH, Grundy W, et al. Studies leading to the identification of ZD1839 (Iressa™): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 2001; 11: 1911-1914.
16. Wissner A, Brawner Floyd M, Rabindran S, et al. Syntheses and EGFR and HER-2kinase inhibitory activities of 4-anilinoquinoline-3-carbonitriles: analogues of three important 4-anilinoquinazolines currently undergoing clinical evaluation as therapeutic antitumor agents. Bioorg Med Chem Lett 2002; 12: 2893.
17. Rusnak DW, Affleck K, Cockerill SG, et al. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res 2001; 61: 7196-7203.
18. Allen LF, Lenehan PF, Eiseman IA, et al. Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer. Semin Oncol 2002; 29(Suppl 11): 11-21.
19. Srinivasan R, Gillett CE, Barnes DM, et al. Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers. Cancer Research 2000; 60: 1483-1487.
20. Kew TY, Bell JA, Pinder SE, et al. c-erbB-4 protein expression in human breast cancer. Br J Cancer 2000; 82: 1163-1170.
21. Suo ZH, Berner HS, Risberg B, et al. Estrogen receptor-alpha and C-ERBB-4 expression in breast carcinomas. Virchows Arch 2001; 439: 62-69.
22. Knowlden JM, Gee JMW, Seery LT, et al. c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer. Oncogene 1998; 17: 1949-1957.
23. Graber HU, Friess H, Kaufmann B, et al. ErbB-4 mRNA expression is decreased in non-metastatic pancreatic cancer. Int J Cancer 1999; 84: 24-27.
24. Haugen DRF, Akslen LA, Varhaug JE, et al. Expression of c-erbB-3 and c-erbB-4 proteins in papillary thyroid carcinomas. Cancer Res 1996; 56: 1184-1188.
25. Gilbertson RJ, Perry RH, Kelly PJ, et al. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res 1997; 57: 3272-3280.
26. Lodge AJ, Anderson JJ, Gullick WJ, et al. Type 1 growth factor receptor expression in node positive breast cancer: adverse prognostic significance of c-erbB-4. J Clin Pathol 2002 (in press).